Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A warranted post regarding two Algernon Pharmaceuticals screenshots on its website (before their website was recently revised) of a "Speculative Buy" opinion by independent investment advisor Christopher Temple. Temple is a popularly known and federally convicted fraudster, and neo-Nazi.
Cool… Thimble… FULL STOP… Bro…
:)
Not even a drop in Bucket more like a drop in thimble
Here’s one to ponder
AGN/PF = 727,537,885 Outstanding.
AGN Neuro = 900,000,000 Outstanding.
Warrants Are Well North Of 1 Billion Combined.
Alpha North Management Probably Has A Hold Of Everything Combined Upwards Of 20%.
Algernon Pharmaceuticals Will Never Uplist To NASDAQ.
It Was The Reason You Were Given For All Of The Stock Split Activity.
If you Rounded Everything To 3 Billion Shares, How Much Would The Market Cap Need To Be To Break Even @ $7.50 USD Per Share?
Insert Jeopardy Game Show Music Here:
~~~~~~~ ~~~~ ~ ~~~~~.
One Contestant Answered:
"Fool Me Once...
Fool Me Twice..." - G.W. Bush
RIP ~ Alex Trebek.
Holla @ me
M$
Outstanding 14,550,757 posted 05/05/2023
https://webfiles.thecse.com/AGNnr050523.pdf?s1D15s.jSGWKuDMQOgJQhRjbY8FCgwF1
Filing that it’s Closed
https://webfiles.thecse.com/AGN_-_CSE_Letter_-_Rights_Offering.pdf?_JRPsqcI6pQi6nS3fuTZjpJvK2ENxAha
Outstanding: 9,666,988 as of April 30, 2023
Monthly 5th Report
https://webfiles.thecse.com/4._Algernon_-_CSE_Form_7_-_April_2023.pdf?yrwmiJUqOadbuiOPBeUElZyTXQW8vjHn
In that link to the Rights Closing of 4,753,369 it quoted this
At closing, the Company issued 4,753,369 units (the “Units”) at the subscription price of $0.25 per Unit for total gross proceeds of approximately $1,188,342
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-Rights-Offering?id=399577
Excerpts from the latest filed MD&A:
Algernon Pharmaceuticals Inc.
MANAGEMENT’S DISCUSSION AND ANALYSIS
For the six months ended February 28, 2023
Dated April 28, 2023
1) Marketing expenses were $887,458 for the six months ended February 28, 2023 (2022 – $266,965). The increase from the six months ended February 28, 2022 resulted from additional marketing activities being performed during the six months ended February 28, 2023, including the Company being the headline sponsor for the 2022 Wonderland Psychedelic Conference in November 2022. Additional promotional activities were performed during the six months ended February 28, 2023.
2) LIQUIDITY AND CAPITAL RESOURCES
Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company’s objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements.
At February 28, 2023, the Company had a working capital deficit of $1,970,610 compared to working capital at August 31, 2022 of $310,999. This included cash and cash equivalents of $220,585 (August 31, 2022 - $1,408,509) available to meet short-term business requirements and current liabilities of $2,447,732 (August 31, 2022 - $2,516,099). The Company’s accounts payable and accrued liabilities have contractual maturities of less than 30 days and are subject to normal trade terms. The Company has no long-term debt.
At present, the Company has no current operating income. The Company will need to raise sufficient working capital to maintain operations. Without additional financing, the Company may not be able to fund its ongoing operations and complete development activities. The Company intends to finance its future requirements through a combination of debt and/or equity issuance. There is no assurance that the company will be able to obtain such financings or obtain them on favourable terms. These uncertainties may cast doubt on the Company’s ability to continue as a going concern.
Full stop
Ya Think The Decision To Continue Prancing Around Penny Land Like A Peacock With Your "Marketing" Money Is Worthy Of A Feather In The CEO's Cap? Monies You Clearly Do Not Have To Waste That's Targeted At Propping Up The "Privately" Traded Subsidiary AGN Neuro?
Any Of You Own Direct Shares Of AGN Neuro or Just Sitting On The Sidelines Hoping Yet Another Disaster Does Not Unfolded To The Tune Of 90% Plus Losses Across The Checker Board?
Meanwhile, Companies Like Bellus Health (NASDAQ: BLU), Bellus Health Was Recently A Two Billion Dollar Buyout Pharma Company That CEO Moreau Has Long Since Tried Tieing A "Competitive Comparison" To It And AGN/PF, Remained Low Key And Data Driven For It's Shareholders. Bellus Health Continue To Be One To Watch As A Lesson On How To Run A Successful And Expeditious Standalone Clinical Trials In The USA Without The Need For Paltry "Tax Rebates" Long After Data Results. The Australian (Land Down Under/Dante's Inferno/Hurry Up And Wait/Purgatory) Clinical Trial angle, IF Chosen Once Again As Part Of A Miserable Marketing Message - "Multinational" Clinical Trial Of It's IFENPRODIL Chronic Cough Angle, And It Will Most Likely Be Yet Another Powergun Nail In The Coffin For Parent Company - Algernon Pharmaceuticals Inc.
Thus, Maybe You should Seriously Consider Buying Direct Shares Of AGN Neuro? It Could Soon Become Your Last Gasp At Recouping Massive Losses From The COVID-19 Era Moving Forward >>>
M$
Outro
If everything flows right there sould be a decimal point move. Moves?
Algernon may bloom. Break out the Truck.
Good thoughtful timing and successful trial data reviews in well written PR's whould help ease the need for shares to finance AGNPFs future work. Should happen. Grant, partnership and ???. Issue the 65% AGN Neuro shares to current holders? It's a spec stock. Could happen
...GLTA...
Great possible dip and longer term thoughts. Math, from the blue truck driver has proven strong, IMO. About time for longs to get a 'breath' and then maybe staying through the news, Long. Got to play the full game/hands/all cards...
Some micro dose @ 4mins +. An actually good video overall about the current micro dose trends..
...GLTA...
..youtube.com/watch?v=eOGG_5FzlJ4
As always, great analysis, agree with all.
After a couple Reverse’s which works out to 1 share from 200 then Forward 4 from 1
So real claim is 1 share from 50
Rights were right to give to holders of shares for .18 $AGNPF or .25 $AGN
I hope it shows 9.6 bought the Right for .18 $AGNPF or .25 $AGN
$2.5M CAD for the Company for $Cash on hand to pay Expenses
Plus those Buying $2.5M @ .18 $AGNPF or .25 $AGN are the shareholders already so the bottom is in
JMO — Expect it to look as a fall but it will be a fake and any wanting to Jump will be bought, has to be better than .18 $AGNPF or .25 $AGN for $2.5M CAD investment — No need to run it up if they can get Shareholders to Jump on keeping it low and Jumpers jump
Another Opinion — News will come but probably guided to sell the $10M USD Nasdaq shares of Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
Under the Reg A+, AGN Neuro will be offering up to 37.5% of its common shares, with majority ownership residing with AGN Pharma.
Meaning if all the Rights get bought
19.3M Outstanding worth $20M USD
$1.03 $AGNPF
Remember the 1 from 50 Splits ?
Gain of .02 $AGNPF if & only if they sell 37.5% $10M Nasdaq Buyers and leave 62.5% for holders in $AGNPF & $AGN
Time for Shareholders to be rewarded some gain somewhere
Yeah I believe News will be quite to get Jumpers to jump and then when their ready for the $10M Nasdaq Investment — News will hit just before Buyers can Buy
JMO
Cool… If you can’t raise money another way, it’s dilute, go bankrupt, or just close the shop… those are the options I see… Bro…
Meaning this next Monthly 5th Report will show how many of the 9.65 million shares outstanding converted their Rights for a .18 $AGNPF or .25 $AGN cost for an additional shares
JMO - Outstanding Gonna Double
Cool… GOLD STANDARD… Bro…
:)
Pharmaceutical Company Sets Gold Standard for New Drugs
https://www.streetwisereports.com/article/2023/04/26/pharmaceutical-company-sets-gold-standard-for-new-drugs.html
What!?…. No wolf tickets for the clown show?…. Bro….
:(
Cool… buying more wolf tickets for the clown show… Bro…
:)
Thanks Money$ waiting for some clarity on my thoughts too …
Another Clown Show response by a CEO in over his head in debt and dishonesty. That email is worthy of a trash can. If Algernon Pharmaceuticals ever survives self-inflicted financial troubles, you'll likely hear the same drumbeat to no end about Bellus Health. As you should be keenly aware of by now, none of the money the CEO is currently trying to raise will go towards a standalone Chronic Cough clinical trial. It will go towards trying to keep the lights on in their virtual company offices somewhere in Canada.
You need real world efficacy of a drug (Data Driven) to prove anything worthwhile ($) in pharmaceuticals. Bellus Health methodically went about the business of doing just that for their shareholders. they didn't spend years wasting money and time chasing rabbits down hellholes in Pennyland. The CEO offers more Lip Service and Hoping Wishing stuff from one year to the next. He simply wants more of your money to dump into his salary and benefits package. He's been very successful at doing just that ever since Calendar Year 2018.
A Data Driven company Algernon Pharmaceuticals is not. You'll see further glaring evidence of that when they pigeonhole another clinical trial in slow roll enrollment rate Australia for "Tax Rebates" received many years later Those at the helm of Algernon Pharmaceuticals are cut from the cloth of Penny Stock operators, through and through (Like The Wolf Of Wall Street). Period.
More Wolf Tickets
M$
P.S. I am not a subscriber of anything coming from Algernon Pharmaceuticals. Thanks for the Heads Up Shell.
Email from CEO of Algernon Pharma - If your on their mailing list you got one today
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Reminds-Shareholders-of-Previously-Announced-Rights-Offering-and-Approaching-Cut-Off-Date-and-T?id=397294
Max2121 stated:
Correction: I meant
You can’t compare two companies and management.
I know that you know much more than me about drugs etc.
Note:
Not afraid to praise you or anyone else when they know more than me. No inferiority complex when someone knows more than me or has better vision than me.
You can’t compare to companies and management.
I know you much more than me about drugs etc.
However, Google who is Roberto Bellini and his father.
Google it again how much he sold his company to Glaxo Smith a while ago.
I believe (95 %) he is involved with Bellus. I have met with both of them and several times with Roberto Bellini.
I can write this, because I don’t own any longer Bellus. Roberto is very smart loyal young man who was running Bellus.
All I am saying manufacturing drug etc is Bellini family business.
Nice… STR8 FACE… FULL STOP… Bro…
:)
"PURE COMPETITOR" BELLUS HEALTH EXPLODES TO UPSIDE
Market Cap Closing In On USD 2 BILLION @ 14.50 per share
https://www.calm-studies.com/#!/
It's Algernon Pharmaceuticals "CEO" who've long since made a comparison of Algernon Pharmaceuticals to what Bellus Health has flawlessly executed in the Chronic Cough area of disease.
It's Algernon Pharmaceuticals "CEO" who sat on the companies best possible chance out the gate (2018/2019) for ALL shareholders to have prospered from the acquisition of it's lead drug IFENPRODIL for Chronic Cough.
It's Algernon Pharmaceuticals "CEO" whose to date still not positioned the company to begin running a standalone Chronic Cough clinical trial for - Yea or Nay - Proof IFENPRODIL is effective at treating Chronic Cough.
It's Algernon Pharmaceuticals "CEO" who told the general public that pursuing Idiopathic Pulmonary Fibrosis was/is a more lucrative route to take for a fledgling pharmaceutical company.
It's Algernon Pharmaceuticals "CEO" whose spent ALL The Money chasing the latest Hot Headline (COVID-19, DMT...) in Pennyland, down a Deep, Dark & Twisted Rabbit Hole, likely to another disastrous conclusion.
What Percentage Of Success (POS) does the "CEO" place on DMT @ Phase 1 or 2...?
It's Algernon Pharmaceuticals "CEO" who spent years kissing the behind of one Kulwant Malhi (King Penny Flipper), and flushing shareholders best interest down the toilet.
Conflicts Of Interest...What Conflicts Of Interest? Who ME ("CEO")?
It's Algernon Pharmaceuticals "CEO" who finds himself at the helm of a company on life support as it tries to raise chump change to keep the lights on @ it's Virtual Offices somewhere throughout Canada.
It's Algernon Pharmaceuticals "CEO" who is counting on YOU to simply let by bygones be bygones, and he's onto bigger and better things for the company, you, and the world at large.
How In The World Algernon Pharmaceuticals "CEO" remains at the helm remains an overwhelming bonkers thought.
Only In Penny World could you tell a story like ^that with a straight face.
STR8 FACE
M$
Yo X! L I F E
Get A Grip On It!
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work chronic kidney disease.
Nash is a big big problem
Notice of Allowance for Method of Use U.S. Patent Application
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Method-of-Use-US-Patent-Application?id=396747
I just received my rights paperwork..
Just as co said I would…
Also there was a bonus shout out about new patent for repurposed NASH drug..
What?
The Legalese For Saying Screw You USA
“RIGHTS” are Trading on CSE for .01 $AGN.RT
https://thecse.com/en/listings/life-sciences/algernon-pharmaceuticals-inc-27april2023-rights
1,000 went for .015 AGN.RT yesterday
Here’s a read of who is the “Dealer”
https://sedar-filings-backup.thecse.com/00037722/2304051646213247.pdf
Got to say good job preparing the stock holders for Doom & Gloom … sure you weren’t hired to ease the pain lol. Your writings and knowledge on here is quite impressive I might say, Ivy League material at its best. Maybe start your own Co lol…you would be good at convincing the stockholders they bought the Diamond in the rough… better than that guy at Algernon, ha!
Outstanding: 9,666,988 posted April 10, 2023
Monthly Report for March
IMO, consistently filling in some of the blanks here (AGNPF), there (AGN), and seemingly everywhere all at once remains a noble cause.
Also, "Parroting" falls into a category of words like Paltry and Pathetic.
Truth is what...Truth?
Is Truth Finite or Infinite?
Multiverse
It's Your World!
Hav @ it
M$
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |